Oppenheimer & Co’s Fulgent Genetics FLGT Stock Holding History

Oppenheimer & Co’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,620	Closed	-$351K	–	1459
2022 Q1	$351K	Sell	5,620 -841	-13%	-$55.4K	0.01%	1125
2021 Q4	$650K	Sell	6,461 -219	-3%	-$19.2K	0.01%	938
2021 Q3	$601K	Sell	6,680 -7,251	-52%	-$659K	0.01%	943
2021 Q2	$1.28M	Buy	13,931 +5,591	+67%	+$446K	0.02%	655
2021 Q1	$806K	Sell	8,340 -1,443	-15%	-$149K	0.02%	780
2020 Q4	$510K	Sell	9,783 -4,373	-31%	-$183K	0.01%	874
2020 Q3	$567K	Buy	+14,156	New	+$443K	0.01%	765

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oppenheimer & Co's FLGT Position: Q2 2022 in Review

Oppenheimer & Co sold out of Fulgent Genetics (FLGT) in Q2 2022, closing a stake of 5,620 shares — an estimated $351K sold.

Oppenheimer & Co first reported a position in FLGT in Q3 2020 and held it in 7 quarters. The position peaked at $1.28M in Q2 2021. 262 funds tracked by Wall St. Rank hold FLGT as of Q2 2022.

Oppenheimer & Co reported no remaining Fulgent Genetics position as of Q2 2022 after selling out during the quarter.
Oppenheimer & Co sold 5,620 Fulgent Genetics shares in Q2 2022, an estimated $351K.
Oppenheimer & Co first reported a position in Fulgent Genetics in Q3 2020 and held it in 7 quarters.
Oppenheimer & Co's Fulgent Genetics position peaked at $1.28M in Q2 2021.
262 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2022.

Based on Oppenheimer & Co's 13F filing for Q2 2022, filed 8 Aug 2022.